US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Travere Therapeutics, Inc. - Common Stock
(NQ:
TVTX
)
56.93
+0.08 (+0.14%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Travere Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026
October 02, 2026
From
Travere Therapeutics, Inc.
Via
Business Wire
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis
September 23, 2026
From
Travere Therapeutics, Inc.
Via
Business Wire
Travere Therapeutics Announces Planned Chief Executive Officer Transition
September 21, 2026
From
Travere Therapeutics, Inc.
Via
Business Wire
Travere Therapeutics (NASDAQ:TVTX) Passes Minervini Trend Template With High-Growth Momentum
↗
September 21, 2026
Via
Chartmill
Travere Therapeutics (NASDAQ:TVTX) Beats Q2 Revenue Estimates on FILSPARI Sales Growth
↗
August 04, 2026
Via
Chartmill
Travere Therapeutics (NASDAQ:TVTX) Earns Perfect Ratings in Breakout Setup Screen
↗
July 28, 2026
Via
Chartmill
Travere Therapeutics (NASDAQ:TVTX): High Growth Momentum Stock with Breakout Setup
↗
July 25, 2026
Via
Chartmill
Travere Therapeutics (NASDAQ:TVTX) - High Growth Momentum and Technical Breakout Setup
↗
July 02, 2026
Via
Chartmill
Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
September 17, 2026
From
Travere Therapeutics, Inc.
Via
Business Wire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 11, 2026
From
Travere Therapeutics, Inc.
Via
Business Wire
Travere Therapeutics Sees FILSPARI FSGS Launch Top Expectations, Expands Renal Pipeline
↗
August 18, 2026
Travere Therapeutics (NASDAQ:TVTX) is pursuing growth through expanded use of FILSPARI in rare kidney diseases while advancing a late-stage treatment candidate for classical homocystinuria and building...
Via
MarketBeat
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 12, 2026
From
Travere Therapeutics, Inc.
Via
Business Wire
Travere Therapeutics (TVTX) Q2 2026 Earnings Call Transcript
↗
August 11, 2026
FILSPARI net sales surged 96% year-over-year, driven by strong FSGS launch demand.
Via
The Motley Fool
Topics
Earnings
Travere Therapeutics to Participate at Upcoming Investor Conferences
August 05, 2026
From
Travere Therapeutics, Inc.
Via
Business Wire
Travere Therapeutics Q2 Earnings Call Highlights
↗
August 04, 2026
Travere Therapeutics (NASDAQ:TVTX) reported second-quarter results marked by record FILSPARI demand and revenue, driven by continued growth in IgA nephropathy and an early launch in focal segmental...
Via
MarketBeat
Topics
Earnings
Travere Therapeutics Reports Second Quarter 2026 Financial Results
August 04, 2026
From
Travere Therapeutics, Inc.
Via
Business Wire
Travere Therapeutics to Report Second Quarter 2026 Financial Results
July 28, 2026
From
Travere Therapeutics, Inc.
Via
Business Wire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 10, 2026
From
Travere Therapeutics, Inc.
Via
Business Wire
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now
↗
June 19, 2026
Mornings like we had on Wednesday are exactly why I get up and do this show every single day the market is open. UniQure NV (QURE) opened around $43. Touched $48.88 intraday. Closed in the high $47s....
Via
InvestorPlace
Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027
June 16, 2026
From
Travere Therapeutics, Inc.
Via
Business Wire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 11, 2026
From
Travere Therapeutics, Inc.
Via
Business Wire
Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress
June 04, 2026
From
Travere Therapeutics, Inc.
Via
Business Wire
Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
June 02, 2026
From
Travere Therapeutics, Inc.
Via
Business Wire
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy
May 27, 2026
From
Travere Therapeutics, Inc.
Via
Business Wire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 12, 2026
From
Travere Therapeutics, Inc.
Via
Business Wire
Validating headline phrasing and editorial resonance A Director Cashes In Near the Top, but What Remains Matters
↗
May 10, 2026
This rare disease therapeutics specialist reported a notable insider sale amid a year of strong share price gains and pipeline progress.
Via
The Motley Fool
Topics
Regulatory Compliance
Travere Therapeutics to Participate at Upcoming Investor Conferences
May 07, 2026
From
Travere Therapeutics, Inc.
Via
Business Wire
Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
May 06, 2026
From
Travere Therapeutics, Inc.
Via
Business Wire
Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
May 05, 2026
From
Travere Therapeutics, Inc.
Via
Business Wire
Travere Therapeutics Analysts Increase Their Forecasts Following Q1 Earnings
↗
May 05, 2026
Travere Therapeutics (NASDAQ:TVTX) reported a profit in Q1, surpassing analyst estimates. Shares fell 1.1% on Tuesday, analysts have raised price targets.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
